

# RNF20 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant RNF20. Catalog # AT3674a

### **Product Information**

Application	WB, E
Primary Accession	<u>Q5VTR2</u>
Other Accession	<u>NM_019592</u>
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG2a Kappa
Clone Names	1C6
Calculated MW	113662

#### **Additional Information**

Gene ID	56254
Other Names	E3 ubiquitin-protein ligase BRE1A, BRE1-A, hBRE1, 632-, RING finger protein 20, RNF20, BRE1A
Target/Specificity	RNF20 (NP_062538, 177 a.a. ~ 276 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	RNF20 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.

## Background

The protein encoded by this gene shares similarity with BRE1 of S. cerevisiae. Yeast BRE1 is a ubiquitin ligase required for the ubiquitination of histone H2B and the methylation of histone H3.

## References

Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Svendsen JM, et al. Cell, 2009 Jul 10. PMID 19596235.RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Kim J, et al. Cell, 2009 May 1. PMID 19410543.Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Liu Z, et al. Mol Biol Cell, 2009 Feb. PMID 19037095.The

histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Shema E, et al. Genes Dev, 2008 Oct 1. PMID 18832071.Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Barber TD, et al. Proc Natl Acad Sci U S A, 2008 Mar 4. PMID 18299561.

#### Images



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.